Abstract
HomeCirculationVol. 125, No. 10Abstract From the Emerging Science Series, February 29, 2012 Free AccessAbstractPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessAbstractPDF/EPUBAbstract From the Emerging Science Series, February 29, 2012 Originally published29 Feb 2012https://doi.org/10.1161/CIR.0b013e31824ef036Circulation. 2012;125:1330–1331Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2012: Previous Version 1 Download figureDownload PowerPointMitral Valve Annuloplasty in Addition to Coronary Artery Bypass Grafting Improves Functional Capacity and Promotes Reverse Left Ventricular Remodelling: Preliminary Results of the Randomised Ischemic Mitral Evaluation TrialK. M. John Chan, John R Pepper, RIME Trial Investigators, Imperial Coll London, Royal Brompton & Harefield NHS Trust, London, United KingdomBackground: The optimal treatment of moderate functional ischemic mitral regurgitation (FIMR) is unknown. There is controversy over whether the addition of mitral valve annuloplasty (MVA) to coronary artery bypass grafting (CABG) improves outcome. Hypothesis: We assessed the hypothesis that MVA in addition to CABG improves functional capacity, reverses left ventricular (LV) remodelling, and reduces mitral regurgitation severity compared to CABG alone. Methods: 60 patients with moderate FIMR (effective regurgitant orifice area 0.2–0.4 cm2) referred for CABG were randomised to either CABG alone (Group 1) or CABG plus MVA (Group 2). Cardiopulmonary exercise testing, echocardiography, cardiovascular magnetic resonance imaging and plasma BNP levels were measured at baseline and one year. Results: At one year following surgery, peak oxygen consumption improved by a significantly greater amount in Group 2 compared to Group 1 (3.0±0.6 ml/kg/min versus 1.0±0.4 ml/kg/min; P=0.008). In addition, left ventricular (LV) volumes, LV sphericity, and mitral regurgitation severity decreased by significantly greater amounts in Group 2 compared to Group 1 (LVESVI decrease 24.4% versus 10.2%, P=0.05; LV sphericity decrease 17.9% versus 1.7% increase, P=0.01; mitral regurgitant volume decrease 69.2% versus 14.5%, P=0.005). Plasma BNP levels were also significantly less in Group 2 compared to Group 1 (54.8±7.2 pmol/l versus 108.9±11.4 pmol/l, P=0.001). Conclusion: Compared to CABG only, the addition of MVA to CABG in moderate FIMR significantly improves functional capacity, reverses LV remodelling, restores LV geometry, and reduces mitral regurgitation severity.K. Chan: None. J.R. Pepper: None. R. Investigators: None. Previous Back to top Next FiguresReferencesRelatedDetails March 13, 2012Vol 125, Issue 10 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/CIR.0b013e31824ef036 Originally publishedFebruary 29, 2012 PDF download Advertisement
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
